WWW.KONF.X-PDF.RU
- , ,
 


Pages:     | 1 |   ...   | 3 | 4 ||

...

-- [ 5 ] --

Kaufinann, G. Bastert // Berlin, Springer-Verlag. 1994. P. 186.

56.Predictors of skeletal complications in patients with metastatic breast carcinoma / S.M. Domchek, J.Younger, D.M. Finkelstein et al. // Cancer. 2000. Vol. 89, 2. P. 363-368.

57.Serum bone-specific alkaline phosphatase as a biomarker for osseous metastases in patients with malignant carcinomas: a systematic review meta-analysis / W.X.

Du, S.F. Duan, J.J. Chen et al. // J. Cancer Res Ther. 2014. Vol.10. Supp 2. P.140-143.

58.Ebert W. Comparison of bone scintigraphy with in the diagnosis of bone metastasis in lung carcinoma patients /W. Ebert, T. Muley, K. Herb, H. Schmidt Gayk//. Anticancer Res. -2004. -Vol.24, 5/ P. 3193- 3201.

59.Eriksen, E.F. The cellular basis of bone remodeling / E.F. Eriksen, M. Kassem // Triangle. 1992. Vol.31. P.45 -57.

60.Positron emission tomography and bone metastases /I. Fogelman, G. Cook, O.

Istrael et al. // Semin Nucl Med. 2005. Vol.35. P.135-142.

61.Diagnostic accuracy of bone metastasis detection in cancer patients: comparison between bone scintigraphy and whole body FDG PET / R. Fujimoto, T.

Higashi, Y. Nakamoto et al. // Annals of Nuclear Medicine. 2006. Vol.26, 6. P 399-408.

62.Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as a serum marker of bone metastases in human breast cancer/ B. Capeller, H.Caffier, M.W. Sutterlin et al.//Anticancer Res. 2003. Vol. 23, 2A. P. 1011-1015.

63.Galasko, C. S. Diagnosis of skeletal metastases and assessment of response to treatment / Metastatic Bone Disease: Fundamental and Clinical Aspects Springer Verlag Berlin Heidelberg.1994. P. 93-108.

64.Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in in breast cancer patients with bone metastases/ D. Generali, A.Dovio, M. Tampellini et al. // British J of Cancer. 2008. Vol. 98. P. 1753- 1758.

65.Cytokines as markers of osteolysis in the diagnostics of patients with bone metastases / M. Groblewska, B. Mroczko, M. Czygier, M. Szmitkowski // Bialystok. 2008. Vol. 62..P. 668-675.

66.Prospective evaluation of the peptide bound collagen type cross linked Ntelopeptide and C telopeptide in predicting bone metastases status / L. Gosta, L.M. Demers, A. Gouneia Oliveirsa at al. //J. Clin Oncol. 2002. Vol. 20. P. 850 - 856.

67.Gremers, S. Bone markers/ S. Gremers, J. P. Bilezikian, P Garnero // New Aspects. Clin. Lab. 2008. Vol. 54 P.461 - 471.

68.Tartrate resistant acid phosphatase 5b (TRACP) as a marker of bone resorption / J.M. Hallen, S.L. Titinen, H.Ylipahkala at al. //Clin Lab.2006. Vol. 52. P.499 509.

69.Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity / V. Hirsh, P.P Major and A.

Lipton at al. // J Thorac Oncol. 2008. Vol. 3. P. 228-236.

70.Increased tartrate-resistant acid phosphatase (TRAP) 5b expression in malignant breast, ovarian and melanoma tissue: an investigational study/ A. Honig, L.

Rieger, M. Kapp et al. //BMC Cancer. 2006. Vol. 6. P. 199.

71.Huang, Q. Biochemical-markers for the diagnosis of bone metastases: a clinical review /. Q. Huang, X. Quyang // Cancer Epidemiology. 2012. Vol. 36. P.

94-98.

72.Hung, M.J. Value of TRAcP 5b as a diagnostic marker for detection of bone metastases in patients with breast cancer / M.J. Hung, G.M. Oremek // Eur J Gynaecol Oncol. 2011. Vol. 32, 6. P.615-618.

73.Diagnostic value of bone- turnover metabolites in the diagnosis of bone metastasis in patients with lung carcinoma/ M. Izumi, Y. Takayama, K.

Kimotsuki et al.// Cancer. 2001. Vol. 91, 8. P.1487-1493.

74.Jung, K. Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers metastasis / K. Jung, M. Lein // Biochim Biophys Acta. 2014. Vol. 1846, 2. P.425 - 438.

75.A multigenis program mediating breast cancer metastasis to bone /Y. Kang, P. M, W. Shu at al // Cancer Cell. 2003. Vol.3. P.537-549.

76.A high incidence of vertebral fracture in women with breast cancer/ J.A. Kanis, E.V. McCloskey, T. Powles at al. //British Journal of Cancer. 1999. Vol. 79. P.1179 - 1181.

77.Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer / Q.Q. Kong, T.W. Sun, Q.Y. Dou at al //- Int J Biol Markers. 2007. Vol. 22, 3. P 214-220.

78.Diagnosis of vertebral metastasis, epidural metastasis, and malignant spinal cord compression: are T(1)-weighted sagittal images sufficient? / J.K. Kim, T.J.

Learch, P.M. Colletti et al. // Magn Reson Imaging. 2000. Vol. 18, 7. P.

819-824.

79.Kominsky, S.L. A"bone" fide predictor of metastases? Predicting breast cancer metastases to the bone / S.L. Kominsky, N.E.Davidson //J Clin Oncol. 2006. Vol. 24. P. 2227 - 2229.

80.Diagnostic bone scanning in oncology/ A.Z. Krasnow, R.S. Hellman, M.E.

Tiwiins et al //Semin Nuc Med. 1997. Vol. 27. P. 107- 141.

81.Osteocalcin and other serum markers of bone metabolism in a healthy population / V. Kusec, M. Kramaric, I. Baric at al. / Clin Lab. 1998. V. 44. P. 277-283.

82.Alpha CTX as a biomarker of skeletal invasion of breast cancer:

immunolocalization and the load dependency of urinary excretion / D. J.

Leeming, G. Delling, M. Koizumi et al. // ancer Epidemiol. Biomarkers Prev. 2006. Vol.15, 7. P. 1392-1395.

83.Relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients / D. J. Leeming, M.

Koizumi, I. Byrjalsen at al. //Cancer Epidemiol. Biomarkers Prev. 2006. Vol.15, 1. P. 32-38.

84.Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic cid for detection of bone metastases progression / M. Lein, M.

Wirth, K. Miller at al. // Eur Urol. 2007. Vol.52, 5. P.1381-1387.

85.Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases/ S.F. Li, X.R.

Wang, C. Wang at al. // Zhonghua Zhong Liu Za Zhi. 2009. Vol.31, 12. P. 911- 915.

86.Modeling the interactinos between osteolast and osteoblast activities in bone remodelling / V. Lemaire, F.L.Tobin, L.D. Greller at al. / J. Theor Biol. 2004. Vol. 229, 3. P. 293 -309.

87.Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity / A. Lipton, R.J. Cook, P. Major at al // Oncologist. 2007. Vol. 12. P. 1035 1043.

88.Systemic Therapy for Bone Metastasis / L.S. Loftus, S. Edwards-Bennett, G. H.

Sokol at al. // Cancer Control. 2012. Vol. 19, 2. P. 145 - 153.

89.Lpez-Carrizosa M.C. Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases/ M.C.

Lpez-Carrizosa, P.M. Samper-Ots, A.R. Prez //Clin. Transl. Oncol. 2010. Vol 12, 8.

90.Normalization of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer/ D.R. Luftner, A. Richter, R.

Geppert et al. //Anticancer Res. 2003. Vol.23, 2A. P.1017-1026.

91.Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases / F. Lumachi, F. Marino, G.Fanti at al. // Preliminary results Anticancer Res. 2011. Vol.31, 11. P. 3879 - 3881.

92.Maeda, H. Correlation between bone metabolic markers and bone scan in prostatic cancer / H. Maeda, M. Koizum K. Yoshimura J. // Urol. 1997 Vol.

157. P. 539-543.

93.Brief courses of palliative radiotherapy for metastatic bone pain: a pilot costminimization comparison with, narcotic analgesics / R.M. Macklis, H. Cornelli, J.

Lasher // Am J Clin Oncol. 1998. Vol.21, 6. P.617-622.

94.Malaver, M. Treatment of metastatic bone disease / M. Malaver // In.:

Musculoskeletal cancer surgery. 2001. P. 216-230.

95.Relative contribution of bone density? Bone turnover and clinical risk factors to long term fracture prediction / L.J. Melton, S.C. Growson, W.M.OFallon at al.

// J Bone Miner Res. 2003. Vol.18. P.312-318.

96.Morony, S. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis cancer research / S. Morony, C. Capparelli, S. Sarosi //. 2001. Vol. 61 . P.

4432-4436.

97.Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data/ G. Mountzios, V. Ramfidis, E. Terpos, K.N. Syrigos /Clinical lung cancer. 2011. Vol. 12, 6. P.341-349.

98.Mundy, G.R. Mechanisms of osteolytic bone destruction / G.R. Mundy, B. F.

Boyce and T. Yoneda // In: Metastatic Bone Disease: Fundamental and Clinical Aspects. Heidelberg. 1994. P. 86 - 92.

99.Mundy, G.R. Metastasis to bone: causes, conseguences and therapeutic opportunities/ G.R. Mundy //Nat. Rev. Cancer. 2002. Vol. 2, 8. P. 584 Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications/ E.C. Nelson, C. P. Evans, C.X. Pan at al. // World J Urol. 2007. Vol. 25. P. 393-399.

101. Nguyen, T. Variability in the measurement of biochemical markers of bone turnover. In: M.J. Seibel, S.P. Robins. J.P. Bilezikian (eds) Dynamics of bone and cartilage metabolism / T. Nguyen, C. Meier, C. Seibel // 2 Edition; Academic Press, San Diego. 2006.

102. Newman, L.A. Evidence-based management of breast cancer/ L.A.

Newman, D.F. Hayes // In: Oncology. An credence based approach. New York: pringer. 2006.

103. Papacbristou, D.J. Bone metastases: moleular mechanisms and therapeutic interventions/ D.J. Papacbristou, E.K. Basdra, A.G. Papavassiliou // Med Res Rev. 2012. Vol.32, 3. P. 611- 636.

104. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid/ D. Pectasides, M. Nikolaou, D. Farmakis et al. //Anticancer Res. 2005. Vol. 25. P. 1457-63.

105. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer / D. Pectasides, D. Farmakis, M.

Nirolaou at al // Pharm Biomed Anal. 2005. Vol.37, 1. P 171-176.

106. Piccart, M.J. Integration of new therapies into management of metastatic breast cancer / M. J Piccart, A. Awada, A. Hamiton // ASCO Educational book. Atlanta. 1999. P.526 - 539.

107. Plunkett, T.A. Risk of complications from bone metastases in breast cancer, implications for management / T.A. Plunkett, P. Smith, R.D. Rubens // Eur J Cancer. 2000. Vol.36, 4. P. 476-482.

108. New and traditional serum markers of bone metabolism in the detection of skeletal metastases/ M. Plebani, D. Bernardi, M.Zaninotto at al // Clin Biochem 29. 1996. P. 67-72.

Circadian variation in serum concentration of C terminal telopeptide of 109.

type collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting / P. Qvisit, S.hristgau, B.J. Pedersen at al // Bone. 2002. Vol. 31, 1. P. 57- 61.

110. Zoledroni acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double- blind, randomized trial- the zoledroni acid lung cancer and other solid tumors study group / S. Rosen, D. Gordon, S. Tchekmedyian at al. //J Clin Oncol. 2003. Vol. 21. P.3150-3157.

111. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study/ P.D. Ross, B.C. Kress, R.E. Parson at al // Osteoporos Int. 2000. Vol. 11. P. 76- 82.

Rubens, R.D. Bone metastases the clinical problem / R.D. Rubens // Eur.

112.

J. Cancer. 1998. Vol. 34, 2. P.210 - 214.

113. Roodman, G. D. Biology of Osteoclast Activation in Cancer / D. Roodman // Journal of Clinical Oncolog/. 2001. - Vol. 19. P. 3562-3571.

114. Roodman, G. D. Mechanisms of Bone Metastasis / G. D. Roodman // The new england journal medicine. 2004. Vol. 350. .1655-1664.

115. Roodman, G. D. Genes associate with abronormal bone cell activity in bone metastasis / G. D. Roodman // Cancer Metastasis Rev. 2012. Vol. 10. P. 1055-1112.

116. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology / G.P. Schmidt.H, Kramer. M.F, Reiser et al. // Top. Magn. Reson. Imaging. 2007. Vol. 18, 3. P. 193-202.

Long-term variability of bone turnover markers in patients with non 117.

metastatic breast cancer/ M.J. Seibel, M. Koeller, B. Van Der Velden, I. Diel // Clin Lab. 2002. Vol. 48, 11. P. 579-582.

118. Markers of bone turnover do not predict bone metastases in breast cancer/

M.J. Seibel, M. Koeller, B. Van Der Velden, I. Die// Clin Lab. 2002. Vol. 48:

P. 583-588.

Biochemical markers of bone turnover: art II:

119. Seibel, M. J. clinical applications in the management of osteoporosis / M. J. Seibel // lin. Biochem Rev. 2006. V 26, 4. P. 97 122.

120. Seibel, M.J. The use of molerular markers of bone turnover in the management of patients with metastatic bone disease/ M.J. Seibel // Clin. Endoc.

2008. Vol.68. P. 839 -849.

121. Bone metastasis: mechanisms and therapeutic opportunities / L.J. Suva, C.

Washan, R. W. Nicolas at al. // Nat. Rev. Endocrinol. 2011. Vol. 7, 4. P.

208 -2018.

122. Clinical significance of the serum cross- linked N-telopeptide of type I collagen as a prognostic marker for non- smallcell lung cancer / M. Tamiya, H.

Suzuki, M. Kobayashi at al. // Clin. Lung Cancer. 2013. Vol. 14. P. 50 54.

123. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients / C.

Tang, Y. Liu, B. Wu et al. // Clin Chim Acta. 2013. Vol. 426. P. 102-107.

124. Taube, T. Tumor invasion to bone. Histomorphometric analysis of bone disease induced by myelomatosis, breast cancer and prostate cancer/ T. Taube // Helsinki. 2000. 81p.

Tartrate resistant acid phosphatase (TRAP) as a serum marker for bone 125.

resorption in breast cancer patients with bone metastases/ S Tauchert, A. Liberto, T. Cordes at al.// Clin Exp Obstet Gynecol. 2009. Vol. 36, 4. P 219 - 225.

126. Urinary pyridinoline and deoxy pyridinoline as potential markers of bone metastasis in patients with prostate cancer/ S. Takeuchi, K. Arai, H. Saitoh at al.// World J Urol. 2007. Vol. 25. P. 393-399.

127. Predictors of fractures in fractures in eiderly women/ A.M. Tromp, M.E.

Oms, . Popp Shijders, J.C. Roos, P. Lips // Osteoporos Int. 2000. Vol.11. P. 134 - 140.

128. Alkaline phosphatase as indicator of bone formation/ Lips // V.O. Van Hoof, A.T. Van Oosterom, L.G. Lepoute, M. E de Broe / / Osteoporos Int. 2000. Vol.11 P. 134 - 140.

129. Increased Dickkropf -1expression in breast cancer bone metastases/ N.

Voorzanger Rousselot, D. Goehrig, F. Journe at al. // Br J Cancer. 2007. V.

97, 7. P. 964 970.

130. Relationships between biochemical and symptomatic response in doubleblind randomized trial of pamidronate for metastatic bone disease / J.J/ Vinholes, O.P. Purohit, M.E. Abbey et al. // Ann. Oncol. 1997. Vol. 8. P. 1243 1250.

131. Evaluation of bone metabolic markers in breast cancer with bone metastasis / N. Wada, M. Fujisaki, T. Ireda, M. Kitajima// Breast Cancer. 2001.

P. 131-137.

132. Measurement of urinary collagen cross- links indicate response to therapy in patients with breast cancer and bone metastases /J. Walls, A. Assiri, A. howell et all //Br J Cancer 80 1999. .1265-1270.

133. Weber, K.L. Management of osseous metastases and impending pathologic fractures/ K.L. Weber, R.L. Theriault // 2008. Vol. 58. P 579-591.

134. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices/ H.W. Woite et al//J Bone Miner Res.1999. Vol. 14. P. 792 801.

135. Yamabuki,. Dikkopf-1 as a Novel Serologic and Prognostic Biomarker for Lung and Esophageal Carcinomas / .Yamabuki, .Takano, S. // Cancer Research 2007. Vol. 67 . 2517-2525.

136. Yang, S.K. The role of PET/CT for evaluating breast cancer / S.K. Yang, N. Cho, W.K. Moon. // Korean J. Radiol. 2007. Vol. 8, 5. P. 429-237.

137. Yasuda, H. Osteoclast differentiation factor is a li-gand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to Transe /Rankl/ H. Yasuda, N.Shim, N. Nakagawa // Proc Natl Acad Sci. US A. 1998.

Vol.95. P. 3597-3602.

138. Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study / M.H. Yilmaz, M. Ozguroglu, D. Mert et al. // Med Oncol. 2007. Vol. 17, 1. P.70-74.

139. Yin, J.J. Mechanisms of cancer metastasis to the bone/ J.J. Yin, C.B.

Pollock, K. Kelly // Cell. Res. 2005. Vol.15. P. 5 - 62.

Elevated serum levels of type collagen degradation marker CTP and 140.

tissue inhibitor of metalloproteinase (TIMP) are associated with poor prognosis in lung cancer / S. Ylisirnio, M. Hoyhtya, R.Makitaro at al. // lin. ancer Res. 2001. Vol.7. P. 1633 - 1637.

141. Yoneda, T. Osteolytic bone disease in breast cancer/ T. Yoneda, A. Sasaki, G.R Mundy // Breast Cancer Res. Treat. 1994. Vol. 32. P. 73- 84.

142. Laboratory evaluation of bone marrow metastasis: single institute study / H.K. Yun, MG. Shin, W. da Kim et al. // Korean Journal Lab Med. 2007. Vol.

27, 2. P. 96-101.

143. Prognostis and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid /X.Zhao, X. Xu, Q. Zhang, J at al. // Bio Med Central. 2011. Vol.11. P.403-405.

144. Changes of bone resorption marker Ntx in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases/Y-Y. Zhao, G. Hou, H. Liao et al. // European J of Cancer. 2011. Vol. 47. P. 848- 853.

145. Value of C- telopeptide- cross- linred type I collagen, osteocalcin, bonespecific alkaline phosphatase and procollagen type I N- terminal propeptide in diagnosis and prognosis of bone metastasis in patients with malignant tumors/ H.

Zhao, K. Han, Z.Wang, at al. // Med Monit. 2011. Vol.17, 11. P 626Diagnostic value of bone metabolic markers ICTP and BAP in patients lung cancer with bone metastases/ Y. Xin, B. Han, J. Lou at al // Zhongguo Fei Ai Za Zhi. 2010. Vol. 13, 10. P. 947-953.

147. Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients/ A. Zissimopoulos, D.

Matthaios, E. Matthaiou at al. //J Buon. 2007. Vol. 12, 4. P 505-511.



Pages:     | 1 |   ...   | 3 | 4 ||

:

() TETRANYCHUS ATLANTICUS MGREGOR : 06.01.07 : ...

14.02.02 : ...

. 14.02.02 : , , 20 ...

: 06.02.02 , , , :...

14.02.01 : , ...

. () 03.02.08 , .. 2015...

06.02.02 , , , : , , ...

03.02.14 2015 ..3 I. . 1.1....

- 03.01.06 ( ) , .. 2014 .....

03.02.03 03.01.06 ( ) ...







 
<<     |    
2016 www.konf.x-pdf.ru - - , ,

, .
, , , , 1-2 .